Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued ...

UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...

Deal builds upon UCB’s position as a leader in immunology innovation and expands capabilities in next-generation biologics ...

Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion ...

This acquisition marks UCB’s second foray into the TCE space – closely following a blockbuster licensing deal with TCE ...

UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager ...

Scientist Elizabeth Ng is clutching a small flask with a clear mixture inside it that she’s just retrieved from inside a ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative ...

UCB to buy clinical-stage biotech company, Candid Therapeuticsfor US$ 2.2 billion: Brussels, Belgium Tuesday, May 5, 2026, 09:00 Hrs [IST] UCB, a global biopharmaceutical company, ...

At the moment, an influenza vaccine called FluMist is the only licensed intranasal vaccine approved for use in humans. The ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

MELBOURNE, 2nd May, 2026 (WAM) -- Australian researchers at the Murdoch Children’s Research Institute (MCRI) in Melbourne said they have developed innovative treatments for blood diseases and cancer ...